Darnitsa and Lumosa sign agreement about distribution of LT1001 extended-release analgesic in Ukraine
According to the agreement, Darnitsa is responsible for the registration, sales, and marketing of LT1001 in Ukraine, and Lumosa is responsible for the supply of LT1001 drug.
LT1001 is the world's first analgesic injection with extended release period. The product is designed to relieve severe and moderate postoperative pain for up to 7 days. Prolonged analgesic effect of LT1001 is achieved with a single intramuscular injection in the postoperative period and does not cause potential dependence and respiratory depression.
Compared to morphine, oxycodone and other analgesics for similar indications, LT1001 provides an enhanced analgesic effect and also has a better safety profile with low potential for abuse.
The LT1001 was approved in Taiwan (2017) and Singapore (2020). Currently there is a third phase of the drug’s clinical trial underway in China and development in the United States.
Darnitsa is one of the largest pharmaceutical companies in Ukraine. The company develops, manufactures and sells generic drugs in 12 ATC classes, including painkillers.
Lumosa Therapeutics is a specialized biotechnology company that develops innovative products to meet unmet medical needs related to strokes and neurological diseases.